<?xml version="1.0" encoding="us-ascii"?><InstanceReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><Version>2.4.0.8</Version><ReportLongName>006 - Disclosure - Summary of Significant Accounting Policies</ReportLongName><DisplayLabelColumn>true</DisplayLabelColumn><ShowElementNames>false</ShowElementNames><RoundingOption /><HasEmbeddedReports>false</HasEmbeddedReports><Columns><Column FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><CurrencyCode /><FootnoteIndexer /><hasSegments>false</hasSegments><hasScenarios>false</hasScenarios><MCU><KeyName /><CurrencySymbol /><contextRef><ContextID>c4_From1Jan2013To30Jun2013</ContextID><EntitySchema>http://www.sec.gov/CIK</EntitySchema><EntityValue>0001368993</EntityValue><PeriodDisplayName /><PeriodType>duration</PeriodType><PeriodStartDate>2013-01-01T00:00:00</PeriodStartDate><PeriodEndDate>2013-06-30T00:00:00</PeriodEndDate><Segments /><Scenarios /></contextRef><UPS /><CurrencyCode /><OriginalCurrencyCode /></MCU><CurrencySymbol /><Labels><Label Key="CalendarSupplement" Id="0" Label="6 Months Ended" /><Label Key="Calendar" Id="1" Label="Jun. 30, 2013" /></Labels></Column></Columns><Rows><Row FlagID="0"><Id>1</Id><IsAbstractGroupTitle>true</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>1</Level><ElementName>us-gaap_AccountingPoliciesAbstract</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText /><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>xbrli:stringItemType</ElementDataType><SimpleDataType>string</SimpleDataType><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Accounting Policies [Abstract]</Label></Row><Row FlagID="0"><Id>2</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>2</Level><ElementName>us-gaap_SignificantAccountingPoliciesTextBlock</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><PreferredLabelRole>terseLabel</PreferredLabelRole><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="c4_From1Jan2013To30Jun2013" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText>&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;NOTE

      2.&amp;#160;&amp;#160;Summary of Significant Accounting

      Policies&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Basis of

      Presentation&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;The Company has

      prepared the accompanying condensed consolidated financial

      statements pursuant to the rules and regulations of the

      Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;).

      Certain information and footnote disclosures normally

      included in consolidated financial statements prepared in

      accordance with accounting principles generally accepted in

      the United States of America have been condensed or omitted

      pursuant to these rules and regulations. These condensed

      consolidated financial statements should be read in

      conjunction with our audited financial statements and

      footnotes related thereto for the year ended

      December&amp;#160;31, 2012, included in our Form&amp;#160;10-K filed

      with the SEC. In the opinion of management, the unaudited

      condensed consolidated financial statements include all

      adjustments (consisting only of normal recurring adjustments)

      necessary to present fairly the Company&amp;#8217;s financial

      position and the results of its operations and cash flows.

      The results of operations for such interim periods are not

      necessarily indicative of the results to be expected for the

      full year.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Basis of

      Consolidation&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;The condensed

      consolidated financial statements include the financial

      statements of WaferGen Bio-systems, Inc. and its

      subsidiaries. All significant transactions and balances

      between the WaferGen Bio-systems, Inc. and its subsidiaries

      have been eliminated in consolidation.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Use of

      Estimates&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;Preparing condensed

      consolidated financial statements requires management to make

      estimates and assumptions that affect the reported amounts of

      assets, liabilities, revenues and expenses. Actual results

      and outcomes could differ from these estimates and

      assumptions.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify"&gt;

      &lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Foreign

      Currencies&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;Assets and liabilities of

      non-U.S. subsidiaries for which the local currency is the

      functional currency are translated into U.S. dollars at the

      exchange rate on the balance sheet date. Revenues and

      expenses are translated at the average rates of exchange

      prevailing during each reporting period. Translation

      adjustments resulting from this process are charged or

      credited to other comprehensive income (loss). Foreign

      exchange gains and losses for assets and liabilities of the

      Company&amp;#8217;s non-U.S. subsidiaries for which the

      functional currency is the U.S. dollar are recorded in

      miscellaneous income (expense) in the Company&amp;#8217;s

      condensed consolidated statements of operations.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Accounts

      Receivable&lt;/font&gt; &amp;#8211;&amp;#160;An allowance for doubtful

      accounts will be recorded based on a combination of

      historical experience, aging analysis, and information on

      specific accounts. Account balances will be written off

      against the allowance after all means of collection have been

      exhausted and the potential for recovery is considered

      remote.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Inventory&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;Inventory

      is recorded at the lower of cost (first-in, first-out) or

      market value. Additionally, the Company evaluates its

      inventory in terms of excess and obsolete exposures and

      records provisions where necessary.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Governmental

      Subsidies&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;Incentives received from

      governments in the form of grants are recorded as a reduction

      in expense in accordance with their purpose. Grants awarded

      for the purpose of matching specified expenditures are not

      recognized until a definitive agreement has been signed by

      both parties; thereafter income is recognized to the extent

      that the related expenses have been incurred. The Company

      recognized governmental subsidies of $69,494 and nil in the

      three months ended June&amp;#160;30, 2013 and 2012, respectively

      and $149,590 and nil in the six months ended June&amp;#160;30,

      2013 and 2012, respectively, which were offset against

      operating expenses in the statement of operations.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Stock-Based

      Compensation&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;The Company measures

      the fair value of all stock-based awards to employees,

      including stock options, on the grant date and records the

      fair value of these awards, net of estimated forfeitures, to

      compensation expense over the service period. The fair value

      of awards to consultants is measured on the dates on which

      performance of services is completed, with interim valuations

      recorded at balance sheet dates while performance is in

      progress. The fair value of options is estimated using the

      Black-Scholes valuation model, and of restricted stock is

      based on the Company&amp;#8217;s closing share price on the

      measurement date.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Change in Fair

      Value of Derivatives&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;The Company

      recognizes its warrants with certain anti-dilution

      protection, the Series&amp;#160;A convertible preference shares

      of its Malaysian subsidiary, and the conversion element of

      its convertible promissory notes and of the Series&amp;#160;B

      convertible preference shares of its Malaysian subsidiary as

      derivative liabilities. Such liabilities are valued when the

      financial instruments are initially issued or the derivative

      first requires recognition and are also revalued at each

      reporting date, with the change in their respective fair

      values being recorded as a gain or loss on revaluation within

      other income and expenses in the statement of operations. The

      Company determines the fair value of all of its derivative

      liabilities using a Monte Carlo Simulation approach, with key

      input variables provided by management.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Warranty

      Reserve&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;The Company&amp;#8217;s standard

      warranty agreement is one year from shipment of certain

      products. The Company accrues for anticipated warranty costs

      upon shipment of these products. The Company&amp;#8217;s warranty

      reserve is based on management&amp;#8217;s judgment regarding

      anticipated rates of warranty claims and associated repair

      costs, and is updated quarterly.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify"&gt;

      &lt;font style="display: inline; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Net Income

      (Loss) Per Share&lt;/font&gt;&amp;#160;&amp;#8211;&amp;#160;Basic net income

      (loss) per share is computed by dividing net income (loss) by

      the weighted average number of common shares outstanding

      during the period. Diluted income (loss) per share is

      calculated by dividing net income (loss) by the weighted

      average number of common shares outstanding plus common share

      equivalents from conversion of dilutive stock options,

      warrants, and restricted stock using the treasury method, and

      convertible securities using the as-converted method, except

      when antidilutive. In the event of a net loss, the effects of

      all potentially dilutive shares are excluded from the diluted

      net loss per share calculation as their inclusion would be

      antidilutive.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;p&gt;

        &lt;font style="font-family: times new roman,times; font-size: 10pt;"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&amp;#160;&amp;#8211;&amp;#160;Certain

        reclassifications have been made to prior periods&amp;#8217;

        data to conform to the current presentation. These

        reclassifications had no effect on reported net

        losses.&lt;/font&gt;

      &lt;/p&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Recent

      Accounting Pronouncements&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;

      &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In

      March&amp;#160;2013, the FASB issued ASU&amp;#160;2013-05,

      &amp;#8220;Foreign Currency Matters (Topic 830): Parent&amp;#8217;s

      Accounting for the Cumulative Translation Adjustment upon

      Derecognition of Certain Subsidiaries or Groups of Assets

      within a Foreign Entity or of an Investment in a Foreign

      Entity&amp;#8221; (&amp;#8220;ASU&amp;#160;2013-05&amp;#8221;).

      ASU&amp;#160;2013-05 clarifies the circumstances under which the

      cumulative translation adjustment arising from the

      consolidation of entities for which the functional currency

      is not the U.S. dollar should be released into net income.

      The Company adopted this guidance effective January&amp;#160;1,

      2013, and its adoption did not have a material impact on the

      Company&amp;#8217;s consolidated financial condition or results

      of operations.&lt;/font&gt;

    &lt;/div&gt;&lt;br/&gt;</NonNumbericText><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>nonnum:textBlockItemType</ElementDataType><SimpleDataType>na</SimpleDataType><ElementDefenition>The entire disclosure for all significant accounting policies of the reporting entity.</ElementDefenition><ElementReferences>Reference 1: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 3

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790



Reference 2: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 1

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790



Reference 3: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 6

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790



Reference 4: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 2

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790



Reference 5: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 5

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790



</ElementReferences><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Significant Accounting Policies [Text Block]</Label></Row></Rows><Footnotes /><IsEquityReport>false</IsEquityReport><ReportName>Summary of Significant Accounting Policies</ReportName><MonetaryRoundingLevel>UnKnown</MonetaryRoundingLevel><SharesRoundingLevel>UnKnown</SharesRoundingLevel><PerShareRoundingLevel>UnKnown</PerShareRoundingLevel><ExchangeRateRoundingLevel>UnKnown</ExchangeRateRoundingLevel><HasCustomUnits>true</HasCustomUnits><IsEmbedReport>false</IsEmbedReport><IsMultiCurrency>false</IsMultiCurrency><ReportType>Sheet</ReportType><RoleURI>http://www.wafergen.com/role/SummaryofSignificantAccountingPolicies</RoleURI><NumberOfCols>1</NumberOfCols><NumberOfRows>2</NumberOfRows></InstanceReport>
